Benitec turns to individual investor for new funds
This article was originally published in Scrip
Executive Summary
The Australian gene silencing firm Benitec has secured around A$2 million ($1.4 million) in new funding from its largest shareholder, saying that the global credit crunch had made it "extremely difficult" to raise capital.